The blood vasculature supplies tissues with nutrients, clears waste products, and carries and directs leukocytes to inflammatory sites. To accomplish these functions, microvessels regulate the extravasation of small molecules, plasma proteins and inflammatory cells. The mechanisms responsible for these events have been the subject of intense investigation and, often, dispute.
Introduction
Vascular permeability takes place by paracellular (intercellular) and/or transcellular routes and occurs in three distinct contexts [1] : basal vascular permeability (BVP) refers to the rapid, paracellular flux of small molecules (water, salts) and the very limited transcellular passage of plasma proteins across normal capillaries. Acute vascular hyperpermeability (AVH) refers to the extensive but time-limited passage of plasma and plasma proteins across postcapillary venules by either paracellular or transcellular routes in acute inflammation. Chronic vascular hyperpermeability (CVH) refers to the extensive extravasation of plasma and plasma proteins from the angiogenic 'mother' vessels of tumors, healing wounds and chronic inflammation [2] . In all cases, the barrier that must be crossed includes endothelial cells (ECs), vascular basement membranes and pericytes. Vascular beds in different tissues may respond differently to different agonists.
The mass of plasma solvent and solutes that crosses the vascular wall depends on three different factors [3 ] : pressure and concentration gradients; hemodynamic forces (blood flow, vascular area available for exchange); and the intrinsic permeability of the vascular wall. Assays such as the Miles assay measure the net effect of all three factors, that is, the flux of solute, often plasma albumin, which extravasates from the mix of different blood vessel types present in tissues. In contrast, intrinsic permeability is determined by measuring several coefficients in individual cannulated blood vessels: L p , hydraulic conductivity, essentially the ease with which water extravasates; s, the reflection coefficient, the fraction of a solute (e.g. albumin) that cannot be dragged across the vessel wall by the convective flux of solvent; and P s , the degree to which the vessel wall restricts the diffusion of a solute.
Discussed below is recent progress in our understanding of vascular permeability under the headings of glycocalyx, caveolae/caveolin-1, sphingosine-1-phosphate (S1P), and signaling mechanisms.
Endothelial cell glycocalyx
There has been longstanding controversy as to whether the structure referred to as the EC glycocalyx exists. Newer methodologies have now confirmed earlier electron microscopic studies, demonstrating that the glycocalyx does exist and has functional importance for vascular permeability. The glycocalyx is an up to 1 mm thick coating of the apical surface of normal vascular endothelium and provides the EC-blood interface. Glycocalyx is comprised of transmembrane proteins, predominantly syndecan-1 and glypicans, and their associated heparan sulfate and chondroitin sulfate side chains.
Chappell et al. [4 ,5] have demonstrated that shedding of the glycocalyx induced by the inflammatory cytokine tumor necrosis factor (TNF)-a or by ischemia-reperfusion causes a substantial increase in vascular permeability to both plasma and colloids. Loss of glycocalyx could be prevented by either antithrombin III or hydrocortisone. In another study, Potter et al. [6 ] degraded the glycocalyx of mouse cremaster microvessels with glycosaminoglycan-digesting enzymes or with TNF-a. Once removed, recovery of the hydrodynamically relevant glycocalyx required 5-7 days. However, glycocalyx was almost entirely absent from cultured ECs and could not be generated, even after prolonged culture, although the ECs produced all of the major glycocalyx constituents.
In a related work, Salmon et al. [3 ] investigated the mechanisms by which angiopoietin 1 (Ang-1), a ligand for the tyrosine kinase receptor Tie-2, affected BVP. They found that Ang-1 reduced L p and increased s in normal mesenteric vessels of frogs and rats lined by continuous endothelium and reduced the L p A of vessels with fenestrated endothelium. Pronase digestion of glycocalyx caused a substantial increase in L p that was mitigated by preperfusion with Ang-1. Also, perfusion with Ang-1 nearly doubled glycocalyx thickness. Together, these studies indicate that Ang-1 reduces BVP to a considerable extent by affecting the glycocalyx and so the coefficients that regulate intrinsic permeability.
Caveolae and its primary structural protein, caveolin-1 Caveolae were first described by Palade and Bruns [7] in capillary ECs as 50-100 nm in diameter, smooth membrane-bound cytoplasmic vesicles. Palade proposed that caveolae shuttled across capillary endothelium, carrying with them 'cargoes' of plasma, and so provided the tissues with the plasma proteins needed for maintaining homeostasis. Paradoxically, several laboratories had reported that plasma albumin was cleared more rapidly in cav-1 À/À than in wild-type mice (see [8 ] ).
Recent work from several laboratories has advanced our understanding of the roles of caveolae and caveolin-1 (cav-1) in regulating vascular permeability. It has long been known that when polymorphonuclear leukocytes (PMNs) and other circulating leukocytes bind to and traverse vascular endothelium, plasma and plasma proteins also leak. The Malik laboratory [9 ] investigated the mechanisms responsible for PMN-induced vascular hyperpermeability. PMNs activated by phorbol ester released mediators (oxidants, proteases) that disrupted interendothelial junctions and so increased paracellular permeability. In contrast, PMNs activated by N-formylmethionine-leucine-phenylalanine (fMLP) increased albumin transcytosis across rat lung microvasculature without opening EC junctions. Several steps were involved: binding of PMNs to ECs; Clustering of inter-cellular adhesion molecule 1 (ICAM-1; also known as CD54); Src activation; and Src phosphorylation of cav-1. Albumin transcytosis could also be enhanced without PMNs by cross-linking ICAM-1; further, anti-ICAM-1 antibodies blocked albumin endocytosis and transcytosis, as well as Src and cav-1 phosphorylation. Knockdown of cav-1 also prevented PMN-induced albumin transcytosis.
These studies were extended to albumin transport in vivo. Perfusion of isolated rat lungs with fMLP-activated PMNs greatly induced albumin hyperpermeability and pulmonary edema; in contrast, transport of mannitol, a low-molecular-weight substance that traverses the endothelial barrier by the paracellular pathway, was not affected. Perfusion with filipin, a cholesterol-binding agent that ablates caveolae, blocked the increased transport of albumin induced by activated PMNs. Administration of cav-1 siRNA also significantly depleted total lung cav-1 expression and caused a significant decrease in basal as well as in PMN-stimulated albumin PS (product of permeability Â vascular surface area). The rapidity with which the siRNA knocked down cav-1 protein activity is surprising. In cav-1 À/À mice, basal albumin PS was reduced and activated PMNs did not increase albumin PS. Studies with sepsisinduced acute respiratory distress syndrome (ARDS) are consistent with these findings in that patients commonly develop extensive extravascular fluid accumulation with intact EC junctions.
PMNs express cav-1 but at much lower levels than ECs [10 ] . Nonetheless, PMN cav-1 was important in regulating endothelial permeability. PMN from cav-1 À/À mice attached to and traversed EC monolayers less effectively than their wild-type counterparts. In vivo, fMLP and platelet-activating factor (PAF)-stimulated PMN from cav-1 À/À mice were much less effective than wild-type PMN in inducing permeability to solute and in crossing the lung endothelial barrier.
Chang et al. [8 ] investigated the role of caveolae, cav-1 and vesiculo-vacuolar organelles (VVOs) in AVH and CVH. VVOs are clusters of hundreds of variably sized, interconnected vesicles and vacuoles that extend across normal venular EC cytoplasm from lumen to ablumen; in response to permeabilizing agents such as histamine or vascular endothelial growth factor (VEGF), they open to provide a transcellular route for plasma protein extravasation in wild-type mice [2, 11] . As expected, caveolae-sized vesicles were strikingly reduced in the capillary and venular endothelium of cav-1 À/À mice [8 ] . Further, nearly all capillary caveolae and similar-sized vesicles in venular endothelium of wild-type mice labeled with anticaveolin antibodies, but only 1/3-1/2 of larger vesicles and vacuoles in VVOs were so labeled. Nonetheless, VVOs were found in equal numbers and with indistinguishable composition in the venular endothelium of cav-1 À/À and wild-type mice. However, VEGF-induced AVH was strikingly reduced in cav-1 À/À mice, despite the presence of normal appearing VVOs. This finding suggests that, although cav-1 is not essential for VVO formation, it is important for VVO function.
These authors also found that transformation of venules into hyperpermeable mother vessels, the initial step in VEGF-induced angiogenesis [2] , is strikingly reduced in cav-1 À/À mice [8 ] . Mother vessel formation was shown to involve digestion of venular vascular basement membranes by pericyte cathepsins, coupled with a simultaneous decrease in cathepsin inhibitors; with loss of basement membrane, pericytes detached and ECs thinned and expanded to cover an enlarged surface area [12 ] . Venular VVOs contributed to this process by donating their membranes to the rapidly expanding plasma membrane. Thus, the failure of mother vessels to form in cav-1 À/À mice in response to VEGF or tumors likely reflects the absence of cav-1 in VVOs, indicating that cav-1 has an important role in VVO function in both AVH and CVH.
Sanchez et al. [13] used mice with genetically modified endothelial nitric oxide synthase (eNOS) and cav-1 to investigate the mechanisms of AVH. They found that eNOS endocytosis by caveolae to an as yet undetermined subcellular target is a necessary step for nitric oxide production and so for the increased AVH induced by PAF and VEGF.
Sphingosine-1-phosphate
Sphingosine-1-phosphate is an important regulator of postcapillary venule permeability. It acts through two receptors, S1P 1 and S1P 2 , which are differentially expressed in different vascular EC beds and can mediate antagonistic activities. Skoura and Hla [14] have recently reviewed S1P, but I summarize here several newer advances. Zhao et al. [15] demonstrated that bone marrow-derived progenitor cells (BMPCs) from wild-type mice acted through the S1P pathway to enhance endothelial barrier function and prevent increased vascular permeability, edema formation and lethality in phorbol ester-challenged mice. BMPC from sphingosine kinase null mice failed to do so, implicating S1P and S1P 1 . Whereas human umbilical vein ECs primarily express S1P 1 , cremaster muscle ECs expresses both S1P 1 and S1P 2 [16 ] . As a result, S1P did little to suppress histamine-induced permeability in cremaster muscle as S1P activated both receptors whose actions are antagonistic. Similarly, Camerer et al. [17 ] generated mice lacking plasma S1P. These mice exhibited greatly increased BVP (lungs > paws) as well as greater AVH to histamine; further, passive systemic anaphylaxis was considerably more lethal than in wild-type mice. Of interest, these mutant mice could be rescued by transfusion of red blood cells, which express sphingosine kinases.
A potpourri of signaling studies
The signaling pathways by which different agonists modulate vascular permeability are a subject of enormous complexity. Significant progress was made in the last year on many different fronts and results from selected studies are presented below.
(1) Pericyte-secreted transforming growth factor (TGF)b has long been known to participate in vessel stabilization in vitro. Walshe et al. [18 ] investigated the role of TGF-b in the retinal vasculature. TGF-b interacts with its receptor, TGFbRII, to recruit and phosphorylate TGFbRI, with subsequent downstream recruitment of smad transcription factors. TGF-b signaling was inhibited by systemic expression of endoglin (TGFbRIII), with a resulting breakdown of the blood-retinal barrier and consequent increased paracellular permeability. ECs express two TGFbRI receptors, ALK5 and ALK1. Signaling through ALK5 stabilizes vascular endothelium, whereas signaling through ALK1 limits ALK5 signaling and causes vascular destabilization. These findings help to elucidate the signaling mechanisms by which pericytes maintain the integrity of the normal retinal microvasculature. (2) The neurotransmitter dopamine was shown some years ago to inhibit VEGF-A-induced CVH and angiogenesis by inhibiting phosphorylation of VEGFR-2 [19] . Sinha et al. [20 ] have now worked out some of the signaling mechanisms. They demonstrated that the dopamine receptor, D2DR, normally co-localizes with VEGFR-2 at the EC surface. On addition of VEGF, SHP-2 translocated from the cytosol to the cell surface and associated with both VEGFR-2 and D2DR. VEGF promoted the dissociation of VEGFR-2 from D2DR and induced VEGFR-2 phosphorylation and downstream signaling. Dopamine pretreatment prevented VEGFR-2 internalization, maintaining the association of D2DR with VEGFR-2. Dopamine also increased the association between SHP-2 and D2DR at the cell surface and stimulated the phosphorylation of SHP-2 and its phosphatase activity. Active SHP-2 inhibited VEGFR-2 phosphorylation at Y951, Y996 and Y1059, but not at Y1175. Decreased phosphorylation of VEGFR-2 at Y951 decreased Src phosphorylation at Y418 and its kinase activity, thus inhibiting VEGF activity. (3) Knezevic et al.
[21 ] investigated the signaling pathways by which PAF increases paracellular permeability. PAF interaction with its receptor activated the Rho GTPase, Rac1. Rac1 and its guanine nucleotide exchange factor, Tiam1, became associated with a membrane fraction from which they co-immunoprecipitated with the PAF receptor. Simultaneously, actin polymerized to form stress fibers, the junctional proteins ZO-1 and vascular endotherlial (VE)-cadherin relocated from interendothelial junctions, and inter-EC gaps formed without cell contractionor activation of RhoA. The response was independent of myosin light chain phosphorylation, and therefore distinct from the permeability responses induced by other agents such as histamine and thrombin. (4) Ramchandran et al. [22 ] investigated the role of Cdc42 in maintaining BVP in lungs. They generated transgenic mice that expressed the dominant active mutant V12Cdc42 protein selectively in ECs. These mice demonstrated a markedly reduced increase in lung microvascular permeability in response to lipopolysaccharide, compared with wild-type mice. Thrombin-induced transendothelial electrical resistance, a measure of open interendothelial junctions, was reduced in monolayers of ECs expressing the V12Cdc42 mutant, although baseline permeability levels were unchanged. RhoA activity was also reduced compared with wild-type ECs, suggesting that Cdc42 functions by counteracting the canonical RhoA pathway of endothelial hyperpermeability. (5) Activated protein C (APC) has been shown to reduce mortality in sepsis patients [23] . Using both in-vivo and in-vitro models, Schuepbach et al. [24 ] demonstrated that this effect was mediated by APC cleavage and thus activation of the thrombin receptor PAR-1. Pharmacological concentrations of APC had powerful barrier protective effects on cultured murine EC monolayers that were mediated through PAR-1 cleavage. Endogenous overexpression or intravenous injection of APC inhibited permeability induced by VEGF in the Miles assay and also protected against pulmonary edema in endotoxemia. As predicted, APC did not significantly alter the vascular barrier function in PAR1-deficient mice. (6) The Sessa lab found that AVH was reduced in Akt-1 À/ À mice [25] . In cultured ECs isolated from Akt-1 À/À mice, histamine gave a blunted increase in transendothelial resistance with reduced phosphorylation of VE-cadherin, steps which lie downstream of eNOS. However, inflammatory cells isolated from Akt-1 À/À mice responded efficiently to inflammatory stimuli in wild-type mice, indicating that the permeability defect in Akt-1 À/À mice is restricted to ECs. (7) Thrombospondin-1 (TSP-1) is a known inhibitor of VEGF-induced permeability and angiogenesis and tumor growth is increased in TSP-1 À/À mice [26] . Zhang et al. [27 ] found that the TSP-1 receptors, CD36 and b-1 integrin subunit, form a complex with VEGFR-2. 3TSR (a recombinant protein comprised of the three type-1 repeats in TSP-1 that represent its antiangiogenic domain) suppressed VEGF-induced vascular permeability and angiogenesis by inhibiting phosphorylation of VEGFR-2, both in vivo and in vitro. Unexpectedly, however, TSP-1 null mice exhibited decreased VEGF-induced phosphorylation of VEGFR-2 in vivo and in vitro and diminished vascular permeability in response to VEGF.
Conclusion
The study has presented a subjective summary of progress made during the last year toward an understanding of the mechanisms of vascular permeability. Despite enormous progress, we still lack a comprehensive picture of the mechanisms by which different agonists induce either paracellular or transcellular permeability. Space limitations made it necessary to eliminate certain important areas of investigation, and the interested reader is referred to a review by Dejana et al. [28] for progress with respect to the control of vascular integrity by endothelial cell junctions.
